Literature DB >> 21804012

Proteasome immunosubunits protect against the development of CD8 T cell-mediated autoimmune diseases.

Dietmar M W Zaiss1, Cornelis P J Bekker, Andrea Gröne, Benedicte A Lie, Alice J A M Sijts.   

Abstract

Exposure of cells to inflammatory cytokines induces the expression of three proteasome immunosubunits, two of which are encoded in the MHC class II region. The induced subunits replace their constitutive homologs in newly formed "so-called" immunoproteasomes. Immunosubunit incorporation enhances the proteasome's proteolytic activity and modifies the proteasome's cleavage-site preferences, which improves the generation of many MHC class I-presented peptides and shapes the fine specificity of pathogen-specific CD8 T cell responses. In this article, we report on a second effect of immunoproteasome formation on CD8 T cell responses. We show that mice deficient for the immunosubunits β5i/low molecular mass polypeptide (LMP7) and β2i/multicatalytic endopeptidase complex-like-1 develop early-stage multiorgan autoimmunity following irradiation and bone marrow transplantation. Disease symptoms are caused by CD8 T cells and are transferable into immunosubunit-deficient, RAG1-deficient mice. Moreover, using the human Type 1 Diabetes Genetics Consortium MHC dataset, we identified two single nucleotide polymorphisms within the β5i/LMP7-encoding gene sequences, which were in strong linkage disequilibrium, as independent genetic risk factors for type 1 diabetes development in humans. Strikingly, these single nucleotide polymorphisms significantly enhanced the risk conferred by HLA haplotypes that were previously shown to predispose for type 1 diabetes. These data suggested that inflammation-induced immunosubunit expression in peripheral tissues constitutes a mechanism that prevents the development of CD8 T cell-mediated autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21804012      PMCID: PMC3159700          DOI: 10.4049/jimmunol.1101003

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

Review 1.  The role of the ubiquitin-proteasome pathway in MHC class I antigen processing: implications for vaccine design.

Authors:  A Sijts; D Zaiss; P M Kloetzel
Journal:  Curr Mol Med       Date:  2001-12       Impact factor: 2.222

Review 2.  Making sense of mass destruction: quantitating MHC class I antigen presentation.

Authors:  Jonathan W Yewdell; Eric Reits; Jacques Neefjes
Journal:  Nat Rev Immunol       Date:  2003-12       Impact factor: 53.106

3.  Dermatomyositis developed in a recipient of allogeneic BMT; the differentiation of chronic GVHD and autoimmune disease.

Authors:  K Sakamoto; T Imamura; F Niwa; S Komori; Y Ishihara; K Shiga; M Ito; H Hosoi
Journal:  Bone Marrow Transplant       Date:  2011-06-13       Impact factor: 5.483

4.  NOD mice are defective in proteasome production and activation of NF-kappaB.

Authors:  T Hayashi; D Faustman
Journal:  Mol Cell Biol       Date:  1999-12       Impact factor: 4.272

5.  Major histocompatibility complex class I-restricted T cells are required for all but the end stages of diabetes development in nonobese diabetic mice and use a prevalent T cell receptor alpha chain gene rearrangement.

Authors:  T P DiLorenzo; R T Graser; T Ono; G J Christianson; H D Chapman; D C Roopenian; S G Nathenson; D V Serreze
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

6.  Mice expressing both B7-1 and viral glycoprotein on pancreatic beta cells along with glycoprotein-specific transgenic T cells develop diabetes due to a breakdown of T-lymphocyte unresponsiveness.

Authors:  D M Harlan; H Hengartner; M L Huang; Y H Kang; R Abe; R W Moreadith; H Pircher; G S Gray; P S Ohashi; G J Freeman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

7.  MHC class I expression in mice lacking the proteasome subunit LMP-7.

Authors:  H J Fehling; W Swat; C Laplace; R Kühn; K Rajewsky; U Müller; H von Boehmer
Journal:  Science       Date:  1994-08-26       Impact factor: 47.728

8.  Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products.

Authors:  R E Toes; A K Nussbaum; S Degermann; M Schirle; N P Emmerich; M Kraft; C Laplace; A Zwinderman; T P Dick; J Müller; B Schönfisch; C Schmid; H J Fehling; S Stevanovic; H G Rammensee; H Schild
Journal:  J Exp Med       Date:  2001-07-02       Impact factor: 14.307

9.  Immunoproteasomes shape immunodominance hierarchies of antiviral CD8(+) T cells at the levels of T cell repertoire and presentation of viral antigens.

Authors:  W Chen; C C Norbury; Y Cho; J W Yewdell; J R Bennink
Journal:  J Exp Med       Date:  2001-06-04       Impact factor: 14.307

10.  Physiological beta cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes model.

Authors:  Shannon Turley; Laurent Poirot; Masakazu Hattori; Christophe Benoist; Diane Mathis
Journal:  J Exp Med       Date:  2003-11-17       Impact factor: 14.307

View more
  28 in total

Review 1.  Immunoproteasomes: structure, function, and antigen presentation.

Authors:  Deborah A Ferrington; Dale S Gregerson
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

2.  Proteomic identification of immunoproteasome accumulation in formalin-fixed rodent spinal cords with experimental autoimmune encephalomyelitis.

Authors:  Mohit Raja Jain; Qing Li; Tong Liu; Joseph Rinaggio; Amit Ketkar; Vincent Tournier; Kiran Madura; Stella Elkabes; Hong Li
Journal:  J Proteome Res       Date:  2012-02-06       Impact factor: 4.466

3.  mTORC1 Coordinates Protein Synthesis and Immunoproteasome Formation via PRAS40 to Prevent Accumulation of Protein Stress.

Authors:  Young Sung Yun; Kwan Hyun Kim; Barbara Tschida; Zohar Sachs; Klara E Noble-Orcutt; Branden S Moriarity; Teng Ai; Rui Ding; Jessica Williams; Liqiang Chen; David Largaespada; Do-Hyung Kim
Journal:  Mol Cell       Date:  2016-02-11       Impact factor: 17.970

4.  Amelioration of autoimmunity with an inhibitor selectively targeting all active centres of the immunoproteasome.

Authors:  Michael Basler; Elmer Maurits; Gerjan de Bruin; Julia Koerner; Herman S Overkleeft; Marcus Groettrup
Journal:  Br J Pharmacol       Date:  2017-11-29       Impact factor: 8.739

5.  Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity.

Authors:  Michael Basler; Michelle M Lindstrom; Jacob J LaStant; J Michael Bradshaw; Timothy D Owens; Christian Schmidt; Elmer Maurits; Christopher Tsu; Herman S Overkleeft; Christopher J Kirk; Claire L Langrish; Marcus Groettrup
Journal:  EMBO Rep       Date:  2018-10-02       Impact factor: 8.807

Review 6.  Defects in retinal pigment epithelial cell proteolysis and the pathology associated with age-related macular degeneration.

Authors:  Deborah A Ferrington; Debasish Sinha; Kai Kaarniranta
Journal:  Prog Retin Eye Res       Date:  2015-09-04       Impact factor: 21.198

Review 7.  Dysfunction in protein clearance by the proteasome: impact on autoinflammatory diseases.

Authors:  Anja Brehm; Elke Krüger
Journal:  Semin Immunopathol       Date:  2015-05-12       Impact factor: 11.759

8.  Immunoproteasome deficiency protects in the retina after optic nerve crush.

Authors:  Nathan J Schuld; Stacy A Hussong; Rebecca J Kapphahn; Ute Lehmann; Heidi Roehrich; Abrar A Rageh; Neal D Heuss; Wendy Bratten; Dale S Gregerson; Deborah A Ferrington
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

9.  Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes.

Authors:  Denise L Faustman; Limei Wang; Yoshiaki Okubo; Douglas Burger; Liqin Ban; Guotong Man; Hui Zheng; David Schoenfeld; Richard Pompei; Joseph Avruch; David M Nathan
Journal:  PLoS One       Date:  2012-08-08       Impact factor: 3.240

10.  Corneal wound healing is compromised by immunoproteasome deficiency.

Authors:  Deborah A Ferrington; Heidi Roehrich; Angela A Chang; Craig W Huang; Marcela Maldonado; Wendy Bratten; Abrar A Rageh; Neal D Heuss; Dale S Gregerson; Elizabeth F Nelson; Ching Yuan
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.